Documents
-
- Download
- Schrader._Br_J_Dermatol._2016._TOX_expression_in_CTCL.
- Not Applicable (or Unknown)
- open access
In Collections
This item can be found in the following collections:
TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4+CD8- phenotype: TOX expression in various types of CTCL
Background
TOX (thymocyte selection-associated high-mobility group box) was shown to be aberrantly expressed in mycosis fungoides (MF) and Sézary syndrome (SS) and is suggested to have additional diagnostic value. However, data on expression in other types of cutaneous T-cell lymphoma (CTCL) are scarce and it is unknown whether TOX is only expressed by MF with a CD4+CD8- phenotype.
Objectives
To investigate TOX expression in various types of CTCL with different T-cell phenotypes.
Methods
Immunohistochemical expression of TOX was evaluated on 153 skin biopsies of 132 patients with CTCL and 60 patients with benign inflammatory dermatoses (BID).
Results
TOX was expressed by more than 50% of the neoplastic T-cells in 49 of 59 patients (83%) with MF, and in 19 of 22 patients (86%) with SS. The TOX+ cases of MF included 34 of 35 cases (97%) with...
Show moreBackground
TOX (thymocyte selection-associated high-mobility group box) was shown to be aberrantly expressed in mycosis fungoides (MF) and Sézary syndrome (SS) and is suggested to have additional diagnostic value. However, data on expression in other types of cutaneous T-cell lymphoma (CTCL) are scarce and it is unknown whether TOX is only expressed by MF with a CD4+CD8- phenotype.
Objectives
To investigate TOX expression in various types of CTCL with different T-cell phenotypes.
Methods
Immunohistochemical expression of TOX was evaluated on 153 skin biopsies of 132 patients with CTCL and 60 patients with benign inflammatory dermatoses (BID).
Results
TOX was expressed by more than 50% of the neoplastic T-cells in 49 of 59 patients (83%) with MF, and in 19 of 22 patients (86%) with SS. The TOX+ cases of MF included 34 of 35 cases (97%) with a CD4+CD8- phenotype, but also five of eight cases (63%) with a CD4-CD8+ phenotype and 10 of 16 cases (63%) with a CD4-CD8- phenotype. TOX expression in other types of CTCL was common but showed variable intensity. Although only 1 of 60 patients (2%) with a BID expressed TOX in > 50% of the skin-infiltrating T cells, some caution is warranted, as the majority of BIDs had TOX+ T cells varying between 11% and 50%.
Conclusions
TOX expression is not tumour specific, is not restricted to CTCL with a CD4+CD8- phenotype, and, on its own, is insufficient for diagnosis of CTCL. However, it may have an adjunctive diagnostic role in conjunction with other clinical and histological data.
Show less- All authors
- Schrader, A.M.R.; Jansen, P.M.; Willemze, R.
- Date
- 2016
- Journal
- British Journal of Dermatology
- Volume
- 175
- Pages
- 382 - 386